Irene Ghobrial, MD

Irene Ghobrial, MD, director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s 

The current standard in multiple myeloma practice is to measure disease burden and assess risk in bone marrow using tests such as fluorescence in situ hybridization (FISH) and cytogenetics. An advancement with CureCloud is the use of a unique, state-of-the-art CLIA-grade liquid biopsy, through which circulating cell-free DNA from a patient blood draw will be analyzed using next-generation sequencing (NGS) to obtain in-depth genomic information on each patient’s specific subtype of myeloma and detect and actionable genomic alterations.

Utilization of NGS is several steps up for precision medicine in myeloma, Ghobrial says. In addition, by participating in CureCloud, both physician and their patients will receive the genomic testing results of the patient’s myeloma, which can help inform and improve physician/patient conversations and decision-making around future treatment options, including clinical trials.

Videos

Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.

Dr. Ghobrial Discusses the Importance of the Multiple Myeloma Research Foundation's CureCloud Study

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.

This trial analyzed the anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide and low-dose dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Patients achieved a nearly 56% overall response rate.

Many patients on the trial were refractory to lenalidomide.

Irene Ghobrial, MD | Authors

Articles

Dr. Ghobrial Discusses the Importance of the Multiple Myeloma Research Foundation's CureCloud Study

A Novel Anti-CXCR4 Antibody for Relapsed/Refractory Multiple Myeloma